Эпилепсия и пароксизмальные состояния (May 2016)

OUR EXPERIENCE IN APPLICATION OF AUTOLOGOUS BONE-MARROW-DERIVED MESENCHYMAL STEM CELLS FOR THERAPY OF PATIENTS WITH SYMPTOMATIC EPILEPSY

  • F. P. Hlebokazov,
  • T. V. Dоkukina,
  • S. I. Ighnatenko,
  • S. M. Кosmacheva,
  • N. V. Goncharova,
  • M. P. Potapnev,
  • M. V. Makhrov,
  • P. P. Korolevich,
  • N. N. Misyuk,
  • I. V. Grigorieva,
  • S. A. Marchuk

Journal volume & issue
Vol. 6, no. 1
pp. 6 – 14

Abstract

Read online

Abstract: an article presented the data on application of autologous multipotent mesenchymal stem cells (MMSCs) from bone marrow for therapy of 10 patients suffering from drug-resistant symptomatic epilepsy. Intravenous injection of 40.0-101.0Ч106 (mean 68.2± 8,48Ч106) MMSCs endolumbal injection of 2.7-8.0Ч106 (mean 6.34±0.72Ч106) neuroinduced MMSCs did non induced in patients unfovarable reactions an complications. Moreover, during 3-11 months of monitoring 5 of 10 patients demonstrated decrease the frequency or disappearance of seizures, severity the incidence of seizures. 2 patients demonstrated increase of cognitive functions, 2 patients – decrease the level of anxiety. We concluded that application of MMSC-base cellular therapy id safe and enable to facilitate seizure status in patients with drug-resistant symptomatic epilepsy.

Keywords